What is Dilon Technologies?
Founded in 1997, Dilon Technologies, Inc. operates as a specialized entity at the intersection of medical device innovation and clinical diagnostics. The company maintains a sophisticated portfolio focused on hemostasis, advanced cancer detection, and airway management solutions. By integrating proprietary technology with rigorous manufacturing standards, Dilon Technologies addresses critical gaps in patient care. Its market position is defined by a commitment to high-precision instrumentation, which serves as a cornerstone for its ongoing expansion into global clinical markets. The firm's ability to secure significant debt and equity financing reflects its status as a mature, enterprise-level player in the life sciences industry.
How much funding has Dilon Technologies raised?
Dilon Technologies has raised a total of $19.6M across 7 funding rounds:
Debt
$660K
Debt
$1.9M
Debt
$4M
Private Equity
$1.9M
Debt
$350K
Private Equity
$9M
Stock/Share Issuance
$1.9M
Debt (2008): $660K, investors not publicly disclosed
Debt (2011): $1.9M, investors not publicly disclosed
Debt (2012): $4M, investors not publicly disclosed
Private Equity (2017): $1.9M, investors not publicly disclosed
Debt (2020): $350K backed by PPP
Private Equity (2025): $9M with participation from JGB Management
Stock/Share Issuance (2025): $1.9M, investors not publicly disclosed
Key Investors in Dilon Technologies
JGB Management
JGB Management Inc. is an alternative asset management firm established in 2005 by Brett Cohen. The company specializes in investing in niche credit-oriented situations and provides strategic investment solutions to meet the needs of their clients.
PPP
Public-Private Partnership
Undisclosed Investors
What's next for Dilon Technologies?
With the recent infusion of $1.9M, Dilon Technologies is well-positioned to accelerate its R&D initiatives and scale its manufacturing capabilities. The strategic focus will likely shift toward optimizing its existing product suite for broader clinical adoption and potentially exploring new frontiers in diagnostic imaging. As the company transitions through this latest growth phase, the emphasis remains on maintaining its competitive edge in cancer detection and hemostasis technologies. Investors and stakeholders will be monitoring the firm's ability to leverage this capital to drive operational efficiency and expand its footprint in the highly competitive medical technology landscape.
See full Dilon Technologies company page
